However, data from cohorts 1 and 2 of the IMVigor 210 study demonstrated no statistically significant difference in response rates in patients with mutant versus wild-type FGFR3 with urothelial carcinoma treated with atezolizumab [19]. This evidence concerns the gene FGFR3 and urothelial carcinoma.